Table 2.
Proportion of remitters with persistent baseline symptoms and treatment-emergent symptoms
| QIDS-SR16 item | n | % with symptom at baseline |
% with persistent baseline symptoms |
% without symptom at baseline, who had it at remission |
|---|---|---|---|---|
| Sleep onset insomnia | 943 | 76.4 | 35.8 | 9.0 |
| Mid-nocturnal insomnia | 943 | 88.9 | 58.8 | 23.8 |
| Early morning insomnia | 942 | 59.5 | 21.1 | 10.0 |
| Hypersomnia | 943 | 32.8 | 44.3 | 14.2 |
| Sad mood | 943 | 97.8 | 27.7 | 4.8 |
| Decreased appetite | 940 | 48.9 | 10.9 | 8.8 |
| Increased appetite | 939 | 26.7 | 12.0 | 9.6 |
| Decreased weight | 938 | 36.5 | 15.5 | 10.7 |
| Increased weight | 942 | 28.0 | 20.8 | 16.1 |
| Concentration/ decision making |
942 | 93.1 | 22.0 | 6.2 |
| Self-view | 942 | 84.0 | 7.5 | 3.3 |
| Suicidal ideation | 942 | 49.6 | 2.4 | 0.2 |
| General interest | 942 | 92.0 | 9.8 | 5.3 |
| Energy | 942 | 92.8 | 23.0 | 5.3 |
| Slowed down | 942 | 76.2 | 6.3 | 4.5 |
| Restlessness | 942 | 66.5 | 18.9 | 8.2 |
For example, 76.4% of participants had sleep onset insomnia at baseline. Of these, 35.8% continued to have sleep onset insomnia at exit. Of all participants who had sleep onset insomnia at exit, 9.0% did not have it at baseline.